Knowledge and Views of Patients With Cardiovascular Disease Toward Pharmacogenomics in The United Arab Emirates

作者：Maram O. Abbas, Azhar T. Rahma, Iffat Elbarazi, Bassam R. Ali, George P. Patrinos, Farah Nagy, Alya Osman, Reem K. Alneyadi, Abdulla Humaid Al-Shamsi, Mohamed Alraqabani, Zeina N. Al-Mahayri, Fatma Al‐Maskari · 发表于：Clinical and Translational Science · 年份：2025 · DOI：10.1111/cts.70300 · 被引用次数：2 · 研究领域：Pharmacogenetics and Drug Metabolism、Pharmaceutical Economics and Policy、Pharmaceutical studies and practices

Pharmacogenomics (PGx) can potentially tailor medication prescriptions to the genetic profiles of individuals, enhancing treatment outcomes and minimizing adverse drug reactions. This study assessed cardiovascular disease (CVD) patients' knowledge and views toward PGx testing in the United Arab Emirates (UAE). A cross-sectional study was conducted among CVD patients attending multiple clinics using a validated, culturally adapted, and piloted bilingual questionnaire. Participants were invited via phone calls or in-person contact at clinics. Data analysis was conducted using SPSS V.29, incorporating descriptive statistics and multivariable logistic regression. A total of 425 responses were analyzed; 67.5% were over 50 years old, and 67.5% held a bachelor's degree. Chronic diseases, excluding CVD, affected 65.2%, with 58.1% reporting medication side effects and 36.5% was hospitalized due to these effects. Knowledge varied, with 55.3% demonstrating good knowledge; 75.3% recognized DNA as gene-based, while 47.5% understood PGx for predicting medication responses. Participants were grouped into three PGx perception clusters: Cluster 1 (33.17%) concerned about risks but valued PGx, Cluster 2 (40.23%) worried about privacy/costs, and Cluster 3 (26.58%) confident in PGx benefits. Safety was the top priority for 60.2% of respondents, 34.8% would not pay for PGx tets, and 35.3% preferred preemptive testing. Regression linked higher PGx knowledge to females, non-healthcare workers, thos...